All In Biotech

Drug Trial Radar · NCT07766369

A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants

A Phase 1, Open-label, 3-Part Study to Assess Potential Drug-Drug Interactions of E2086 When Coadministered Orally With Itraconazole, Carbamazepine, Midazolam, Dextromethorphan, Bupropion, or Combined Oral Contraceptives in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

93

Planned (sponsor's estimate)

Start

Aug 12, 2026

Primary completion

Nov 12, 2026

Study completion Nov 12, 2026

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess potential drug-drug interactions of E2086 when coadministered orally with Itraconazole, Carbamazepine, Midazolam, Dextromethorphan, Bupropion, or Combined Oral Contraceptives in Healthy Participants

Conditions

  • Healthy Volunteers

Interventions

  • E2086Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A, area under concentration versus time curve from zero time (predose) to time of last quantifiable concentration AUC(0-t) of E2086 and its Metabolite M1Time frame: Day 1 to Day 4; Day 7 to Day 13
  2. Part A, area under concentration versus time curve from zero time (predose) to infinite time AUC(0-inf) of E2086 and its Metabolite M1Time frame: Day 1 to Day 4; Day 7 to Day 13
  3. Part A, maximum observed concentration (Cmax) of E2086 and its Metabolite M1Time frame: Day 1; Day 7
  4. Part B, AUC(0-t) of midazolam (MDZ)Time frame: Day 1 to Day 4; Day 15 to Day 18
  5. Part B, AUC(0-t) of dextromethorphan (DEX)Time frame: Day 1 to Day 4; Day 15 to Day 18
  6. Part B, AUC(0-t) of bupropion (BUP)Time frame: Day 4 to Day 8; Day 18 to Day 22
  7. Part B, AUC(0-t) of hydroxybupropionTime frame: Day 4 to Day 8; Day 18 to Day 22
  8. Part B, AUC(0-inf) of MDZTime frame: Day 1 to Day 4; Day 15 to Day 18
  9. Part B, AUC(0-inf) of DEXTime frame: Day 1 to Day 4; Day 15 to Day 18
  10. Part B, AUC(0-inf) of BUPTime frame: Day 4 to Day 8; Day 18 to Day 22
  11. Part B, AUC(0-inf) of hydroxybupropionTime frame: Day 4 to Day 8; Day 18 to Day 22
  12. Part B, Cmax of MDZTime frame: Day 1 and Day 15
  13. Part B, Cmax of DEXTime frame: Day 1 and Day 15
  14. Part B, Cmax of BUPTime frame: Day 4 and Day 18
  15. Part B, Cmax of hydroxybupropionTime frame: Day 4 and Day 18
  16. Part C, AUC(0-t) of ethinyl estradiol (EE)Time frame: Day 1 to Day 5; Day 12 to Day 16
  17. Part C, AUC(0-t) of norethindrone (NET)Time frame: Day 1 to Day 5; Day 12 to Day 16
  18. Part C, AUC(0-inf) of EETime frame: Day 1 to Day 5; Day 12 to Day 16
  19. Part C, AUC(0-inf) of NETTime frame: Day 1 to Day 5; Day 12 to Day 16
  20. Part C, Cmax of EETime frame: Day 1; Day 12
  21. Part C, Cmax of NETTime frame: Day 1 and Day 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Austin Clinical Research Unit (CRU)- Phase 1

    Austin, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.